Abstract
Background: Juvenile dermatomyosis (JDM) is a rare disease, although it is the most common inflammatory myopathy in childhood. The early therapy has been shown to considerably decrease disease morbidity and mortality. Due to the rarity of JDM, describing new cases becomes of great value for the process of continuing medical education in Pediatrics.
Aim: To report a single case of JDM treated at our Service. Case Report: This was a patient with a history of delay in motor development, who was admitted to our Service at the age of two due to a fracture of the left femur. After the first hospitalization, she continued with follow-up in outpatient clinics of different specialties, in an attempt to investigate her condition in a multidisciplinary way. Later, she was admitted again with fever and pain in the right upper limb. During follow-up with the rheumatologist, it was observed that the patient had characteristic manifestations of JDM, such as photosensitive malar rash, heliotropes and Gottron's papules. Subsequently, she started treatment with methylprednisolone in pulse therapy for three days, in addition to cyclophosphamide cycles, ending the therapy with prednisone 2mg / kg / day. Since then, the patient has been followed up.
Conclusion: JDM, despite its usual rarity, has characteristic signs such as photosensitive malar rash, proximal myopathy, heliotropes and Gottron's papules, which should always be considered in the early diagnosis and treatment. Furthermore, the identification of specific antibodies can be useful for the diagnosis of most patients, and unusual signs such as chorioretinopathy may indicate the presence of the disease.
References
AL-MAYOUF, S. M. et al. Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatology International, v. 37, n. 9, p. 1513–1517, set. 2017.
BELLUTTI ENDERS, F. et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Annals of the Rheumatic Diseases, v. 76, n. 2, p. 329–340, fev. 2017.
BOHAN, A.; PETER, J. B. Polymyositis and Dermatomyositis: (First of Two Parts). New England Journal of Medicine, v. 292, n. 7, p. 344–347, 1975a.
BOHAN, A.; PETER, J. B. Polymyositis and Dermatomyositis: (Second of Two Parts). New England Journal of Medicine, v. 292, n. 8, p. 403–407, 1975b.
CALLEN, J. P. Dermatomyositis. Lancet (London, England), v. 355, n. 9197, p. 53–57, 1 jan. 2000.
CHOI, R. Y. et al. Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. Ocular Immunology and Inflammation, v. 26, n. 6, p. 929–933, 2018.
DEAKIN, C. T. et al. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis & Rheumatology (Hoboken, N.J.), v. 68, n. 11, p. 2806–2816, nov. 2016.
FELDMAN, B. M. et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet (London, England), v. 371, n. 9631, p. 2201–2212, 28 jun. 2008.
FISLER, R. E. et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. Journal of the American Academy of Dermatology, v. 47, n. 4, p. 505–511, out. 2002.
HARRIS-LOVE, M. O. et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford, England), v. 48, n. 2, p. 134–139, fev. 2009.
IWATA, N. et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Modern Rheumatology, v. 29, n. 5, p. 802–807, set. 2019.
KWA, M. C.; SILVERBERG, J. I.; ARDALAN, K. Inpatient burden of juvenile dermatomyositis among children in the United States. Pediatric Rheumatology Online Journal, v. 16, n. 1, p. 70, 13 nov. 2018.
LADD, P. E. et al. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR. American journal of roentgenology, v. 197, n. 1, p. W153-158, jul. 2011.
LI, D.; TANSLEY, S. L. Juvenile Dermatomyositis-Clinical Phenotypes. Current Rheumatology Reports, v. 21, n. 12, p. 74, 11 dez. 2019.
LUNDBERG, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, v. 76, n. 12, p. 1955–1964, dez. 2017.
MAMYROVA, G. et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology (Oxford, England), v. 56, n. 8, p. 1342–1347, 1 ago. 2017.
MASSA, M. et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis and Rheumatism, v. 46, n. 11, p. 3015–3025, nov. 2002.
MENDEZ, E. P. et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis and Rheumatism, v. 49, n. 3, p. 300–305, 15 jun. 2003.
MUSSA, F.; NALITOLELA, N.; FREDRICK, F. An 8-year-old-girl with juvenile dermatomyositis and autoimmune thyroiditis in Tanzania: a case report. Journal of Medical Case Reports, v. 15, n. 1, p. 632, 27 dez. 2021.
NA, S.-J. et al. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. Journal of Korean Medical Science, v. 24, n. 4, p. 715–721, ago. 2009.
NAIM, M. Y.; REED, A. M. Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy. The Journal of Rheumatology, v. 33, n. 7, p. 1392–1394, jul. 2006.
OYEDEJI, O. A. et al. Juvenile Dermatomyositis in an 11 Year Old Nigerian-Boy: A Case Report and Review of Literature. Nigerian Medical Journal: Journal of the Nigeria Medical Association, v. 61, n. 5, p. 284–287, out. 2020.
PAPADOPOULOU, C.; MCCANN, L. J. The Vasculopathy of Juvenile Dermatomyositis. Frontiers in Pediatrics, v. 6, p. 284, 2018.
REED, A. M.; PACHMAN, L.; OBER, C. Molecular genetic studies of major histocompatibility complex genes in children with Juvenile dermatomyositis: Increased risk associated with HLA-DQA1∗0501. Human Immunology, v. 32, n. 4, p. 235–240, 1 dez. 1991.
RIDER, L. G. et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine, v. 92, n. 4, p. 223–243, jul. 2013.
RIDER, L. G.; NISTALA, K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. Journal of Internal Medicine, v. 280, n. 1, p. 24–38, jul. 2016.
ROSA NETO, N. S.; GOLDENSTEIN-SCHAINBERG, C. Dermatomiosite juvenil: revisão e atualização em patogênese e tratamento. Revista Brasileira de Reumatologia, v. 50, p. 299–312, jun. 2010.
SCHMIDT, J. Current Classification and Management of Inflammatory Myopathies. Journal of Neuromuscular Diseases, v. 5, n. 2, p. 109–129, 2018.
SPENCER, C. H. et al. Course of treated juvenile dermatomyositis. The Journal of Pediatrics, v. 105, n. 3, p. 399–408, set. 1984.
STRINGER, E.; FELDMAN, B. M. Advances in the treatment of juvenile dermatomyositis. Current Opinion in Rheumatology, v. 18, n. 5, p. 503–506, set. 2006.
STRINGER, E.; SINGH-GREWAL, D.; FELDMAN, B. M. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis and Rheumatism, v. 58, n. 11, p. 3585–3592, nov. 2008.
SWAFFORD, C.; ROACH, E. S. Juvenile Dermatomyositis and the Inflammatory Myopathies. Seminars in Neurology, v. 40, n. 3, p. 342–348, jun. 2020.
SYMMONS, D. P.; SILLS, J. A.; DAVIS, S. M. The incidence of juvenile dermatomyositis: results from a nation-wide study. British Journal of Rheumatology, v. 34, n. 8, p. 732–736, ago. 1995.
TANSLEY, S. L. et al. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. Journal of Autoimmunity, v. 84, p. 55–64, nov. 2017.
UKICHI, T. et al. MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis. RMD open, v. 5, n. 1, p. e000850, 2019.
VOLOCHAYEV, R. et al. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. The Open Rheumatology Journal, v. 6, p. 54–63, 2012.
WIENKE, J. et al. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Frontiers in Immunology, v. 9, p. 2951, 2018.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.